The Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium (AMP® BGTC) is pleased to announce the completion of the first step of the disease selection process.
FNIH Biomarkers Consortium Project Will Establish New Methods for Detecting Disease in Acute Myeloid Leukemia
The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) has launched a project to validate new methods of detecting and quantifying the small amount of cancer cells remaining in the body following anti-cancer therapy, or measurable residual disease (MRD), in patients with acute myeloid leukemia (AML).
NIMBLE Program Presents First Set of Data on Establishing Non-Invasive Biomarkers to Diagnose Non-Alcoholic Steatohepatitis
North Bethesda, MD, November 15, 2021 – The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, in a groundbreaking program – Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE).
FNIH Biomarkers Consortium Confirms Blood Tests Provide a Key Research Tool for Measuring Amyloid Accumulation in Alzheimer’s Disease
North Bethesda, MD, July 26, 2021—The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) has evaluated several blood tests that can detect one of the known characteristics of Alzheimer’s disease (AD).
June 24, 2021 — Read an interview with Dr. Gerard Honig, project team co-chair and Director of Research Innovation at the Crohn’s & Colitis Foundation.
April 13, 2021 — The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has launched a new project that will establish a common and harmonized methodology to define and measure healing in ulcerative colitis (UC).
January 25, 2021 — The FNIH Biomarkers Consortium “A Novel Total Lesional Automated Computerized Imaging Platform, Biomarker, and Predictive Model for Metastatic Prostate Cancer Project (NiP- Metastatic Prostate Cancer) is an off-shoot of the FNIH Biomarkers Consortium Vol-PACT project that closed December 2020.
Three Questions with Sarcopenia 2 Principal Investigators Dr. Shalender Bhasin and Dr. Peggy Cawthon
September 21, 2020 — The FNIH Biomarkers Consortium Sarcopenia 2 project, Sarcopenia as a Valid Biomarker for Identifying Individuals at Risk of Disability, recently achieved the key milestone of publishing seven articles in The Journal of the American Geriatrics Society and The Journals of Gerontology.